<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154388</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571B2225</org_study_id>
    <nct_id>NCT00154388</nct_id>
  </id_info>
  <brief_title>Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases</brief_title>
  <official_title>Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening
      rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine
      kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that
      specific disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate-sensitive tyrosine kinases</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of Imatinib mesylate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic profile of Imatinib mesylate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess, where feasible, the functional significance of relevant signal-transduction components in target tissues</measure>
  </secondary_outcome>
  <enrollment type="Actual">185</enrollment>
  <condition>Life Threatening Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥ 15 years of age

          -  Life threatening disease documented by conventional criteria to be resistant to
             standard, approved therapy.

          -  Experimental documentation of functional significance of either Abl, Kit (CD117), or
             PDGF-R in the relevant target tissue (preferably on a sample taken within 6 weeks of
             study entry).

          -  ECOG Performance status of 0, 1, or 2.

          -  Adequate end organ function defined as: total bilirubin &lt; 1.5 x ULN, SGOT and SGPT &lt;
             2.5 x UNL (or &lt; 5 x ULN for patients with hepatic disease), creatinine &lt; 1.5 x ULN,
             ANC &gt; 1.5 x 109/L, platelets &gt; 100 x 109/L.

          -  Negative serum or urine pregnancy test for women of child bearing potential (WOCBP)
             within 7 days of study initiation. Post menopausal women must have experienced
             amenorrhea for at least 12 months. Male and female patients must use effective birth
             control methods throughout the study and for up to 3 months after study
             discontinuation.

          -  Life expectancy of more than 3 months.

          -  Written, voluntary, informed consent for retrieval, evaluation and investigational use
             of tissue samples.

        Exclusion Criteria:

          -  Patients who have received any other investigational agent within 28 days of study
             initiation.

          -  Patients with another primary malignancy except if other primary malignancy is neither
             currently clinically significant nor requiring active intervention.

          -  Patients with Grade III/IV cardiac problems defined by the New York Heart Association
             Criteria (e.g. congestive heart failure, myocardial infarction within 6 months of
             study).

          -  Female patients who are pregnant or breast-feeding.

          -  Patients who have another severe and/or life threatening medical disease.

          -  Patients with acute or known chronic liver disease (e.g. chronic active hepatitis,
             cirrhosis).

          -  Patients with a known diagnosis of the human immunodeficiency virus ((HIV) infection.

          -  Patients who have received chemotherapy within 4 weeks (6 weeks allowed for
             nitrosourea, mitomycin-C or any antibody therapy) prior to study entry.

          -  Patients who have had major surgery within 2 weeks prior to study entry.

          -  Patients with any significant history of non-compliance to medical regimens or with
             inability to grant reliable informed consent.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Heinrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2937</url>
    <description>Results for CSTI571B2225 from the Novartis Clinical Trials website</description>
  </link>
  <results_reference>
    <citation>Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009 Jul 1;27(19):3148-53. doi: 10.1200/JCO.2008.20.5054. Epub 2009 May 18. Erratum in: J Clin Oncol. 2009 Sep 20;27(27):4630. Myers, Paul A [corrected to Meyers, Paul A].</citation>
    <PMID>19451433</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>November 16, 2016</last_update_submitted>
  <last_update_submitted_qc>November 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>leiomyosarcoma</keyword>
  <keyword>angiosarcoma</keyword>
  <keyword>synovial sarcoma</keyword>
  <keyword>myelodysplastic syndrome/HES</keyword>
  <keyword>CMML</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>embryonal rhabdomyosarcoma</keyword>
  <keyword>endometrial sarcoma</keyword>
  <keyword>adenoid cystic carcinoma</keyword>
  <keyword>fibromatosis</keyword>
  <keyword>ductal invasive breast carcinoma</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>pleural tumor</keyword>
  <keyword>brenner tumor</keyword>
  <keyword>ewing sarcoma</keyword>
  <keyword>round cell tumor</keyword>
  <keyword>seminoma</keyword>
  <keyword>thymic carcinoma</keyword>
  <keyword>malignant melanoma</keyword>
  <keyword>fibrosarcoma breast</keyword>
  <keyword>dermatofibrosarcoma protuberans</keyword>
  <keyword>DFSP</keyword>
  <keyword>ovarian stromal tumor</keyword>
  <keyword>osteosarcoma</keyword>
  <keyword>chorioideal melanoma</keyword>
  <keyword>hemangiopericytoma</keyword>
  <keyword>myelofibrosis</keyword>
  <keyword>liposarcoma</keyword>
  <keyword>SCLC</keyword>
  <keyword>small cell lung carcinoma</keyword>
  <keyword>hypereosinophilic syndrome</keyword>
  <keyword>chronic myelo-monocytic leukemia</keyword>
  <keyword>neurofibrosarcoma</keyword>
  <keyword>mesothelioma</keyword>
  <keyword>malignant mesenchymoma</keyword>
  <keyword>malignant schwannoma</keyword>
  <keyword>mast cell leukemia / mastocytosis</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>malignant histocytoma</keyword>
  <keyword>chordoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

